You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment

The percentage of adolescent and adult patients with a new episode of alcohol or other drug (AOD) dependence who received the following.
- Initiation of AOD Treatment. The percentage of patients who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis.
- Engagement of AOD Treatment. The percentage of patients who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit.

Date Reviewed: July 21, 2018

Measure Info

MIPS 305NQF 0004CMS 305NQF Endorsed
Measure Type: 
Process
Measure Steward: 
National Committee for Quality Assurance
Clinical Topic Area: 
Prevention and Wellness
Substance Use

Care Setting: 
Emergency Department and Services
Inpatient
Outpatient
Data Source: 
Claims
Electronic Health Records

ACP does not support MIPS measure #305 (NQF measure #0004): “Initiation and Engagement of Alcohol and Other Drug Dependence Treatment” because the specifications are flawed and the measure is not appropriately specified to evaluate performance at the level of the individual clinician.

Developers should consider dividing the numerator statement to form two discrete measures: 1) initiation of alcohol and other drug dependence treatment; and 2) engagement of alcohol and other drug dependence treatment. Also, it is unclear what constitutes a “new episode of drug or alcohol dependency.”

While it is appropriate for accreditors and regulators to use this measure in programs designed to assess quality at the level of the health system, regulators should not include this measure in accountability programs designed to assess performance of individual clinicians. It is unclear whether individual clinicians will be able to control the outcomes of this measure. Individual clinicians will likely face interoperability challenges to data collection.